Trial
NCT06654050
Alrizomadlin (APG-115) in Subjects With BAP1 Cancer Syndrome and Early-Stage Mesothelioma
Phase IIWITHDRAWNOTHER/UNKNOWNConfidence: LOW
Sponsor
National Cancer Institute (NCI)
Collaborators
—
Condition
Mesothelioma
Intervention
alrizomadlin
Why stopped
The study is being withdrawn due to the CRADA with the company not being finalized
Provenance
Dataset: 2026-07-02 • Source: ClinicalTrials.gov API v2 • Last update: 2026-03-17